REVENUE (Tables)

12 Months Ended

Dec. 31, 2020

Revenue from Contract with Customer [Abstract]

Schedule of disaggregated revenue from contracts with customers

The following table reflects summary revenues the years ended December 31, 2020 and 2019 (in thousands):

	Year ended December 31,
	2020		2019
Product sales, net:
INDOCIN Products (1)	$	31,684	$	—
CAMBIA	28,350		32,453
Zipsor	13,286		12,498
SPRIX ((1)	11,077		—
Other (2)	9,101		63,855
Total product sales, net	93,498		108,806
Commercialization agreement revenue, net	11,258		118,614
Royalties and milestone revenue	1,519		2,084
Total revenues	$	106,275	$	229,504

(1)Products acquired in connection with Zyla Merger represent product sales, net for the period of May 20, 2020 through December 31, 2020.

(2)Includes product sales for Gralise, which was divested in January 2020; product sales adjustments for previously divested products NUCYNTA and Lazanda; and, product sales for non-promoted products OXAYDO and SOLUMATRIX, which were acquired from Zyla in May 2020.

Summary of contract assets

The following table reflects changes in the Company’s contract asset as of December 31, 2020 (in thousands):

	Balance as of						Balance as of
	December 31, 2019		Additions		Deductions		December 31, 2020
Contract assets:
Contract asset - Collegium, net	1,896		—		(1,896)		—
	$	1,896	$	—	$	(1,896)	$	—